BenzingaAugust 14, 2026 at 6:18 AM NY21 days ago

Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story